Tirzepatide after adrenalectomy for MACS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, Phase 2 trial enrolling adults with MACS undergoing unilateral adrenalectomy. After surgery, participants are assigned 1:1 to either adrenalectomy alone or adrenalectomy plus tirzepatide for 12 months, with dosing managed per standard care. The primary outcome is blood pressure at 12 months, with secondary measures including weight, BMI, glycemic control, medication burden, and quality of life. The study will assess feasibility, safety, and potential additional metabolic benefits of combining tirzepatide with surgical treatment for MACS. Conducted at the University of Pittsburgh Medical Center, led by Alaa Sada.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years and older
* Diagnosis of MACS, defined as morning cortisol \>1.8 mcg/dL after a 1 mg dexamethasone suppression test
* Elevated blood pressure (SBP ≥120 mmHg or DBP ≥80 mmHg per the 2025 American College of Cardiology/American Heart Association \[ACC/AHA\] criteria, or current use of antihypertensive medication)
* BMI ≥27
* Undergoing or having undergone adrenalectomy for the treatment of MACS

Exclusion Criteria:

* Bilateral adrenal lesions
* Adrenal malignancy
* Concurrent primary aldosteronism with MACS
* Current use of GLP-1 receptor agonists
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
* Pregnancy or breastfeeding

Where it's running

• University of Pittsburgh Medical Center
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Alaa Sada, MD — University of Pittsburgh
• Study coordinator: Meghan Kelley
• Email: hilkoml@upmc.edu
• Phone: 4125789429

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omitting preoperative alpha-blockade for normotensive pheochromocytoma

  This study is testing whether skipping a common medication before surgery can help patients with certain tumors avoid low blood pressure during and after their operation without putting them at risk.

  Recruiting Phase 4 Seoul National University Hospital · Seoul · NCT05702944

• 3D laparoscopic surgery for adrenal tumors

  This study is testing whether using advanced 3D laparoscopic surgery for removing adrenal tumors can make the surgery safer and more precise for patients.

  Recruiting Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta · Girona, Girona · NCT04905706

• Adrenal Diseases in Modena: A Patient Registry at Modena University Hospital

  This study collects medical histories and treatment data from patients with adrenal diseases to see how they are diagnosed and managed in Modena.

  Recruiting Azienda Ospedaliero-Universitaria di Modena · Modena, Modena · NCT07920198

• Robotic adrenalectomy with imaging to guide dissection using a dye

  A randomized comparison tests whether adding indocyanine green (ICG) imaging during robotic adrenalectomy helps surgeons find the adrenal gland and perform the operation.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07813247

• Radiofrequency Ablation vs Adrenalectomy for unilateral aldosterone-producing adenoma with hypertension

  This study tests whether radiofrequency ablation can match adrenalectomy in treating unilateral aldosterone-producing adenoma causing high blood pressure.

  Recruiting University Hospital, Toulouse · Toulouse · NCT07470580

• Italian questionnaire to measure knowledge and vaccination attitudes in people without a spleen

  This project will test a new Italian questionnaire to measure how much people without a spleen know about infection prevention and vaccination.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, Lazio · NCT07428005

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.